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Recent trial results have shown that carotid
endarterectomy can reduce the risk of stroke among
patients with severe carotid stenosis.1-4 With serial
carotid duplex scan surveillance for patients who were
asymptomatic at a large Veteran’s Administration
Hospital, we found that the risk of disease progression
is substantial.5 We observed an annualized progres-
sion risk of 9.3% in the at-risk population.5 Although
our previous study helped to delineate the natural his-
tory of progression of carotid stenosis, it failed to
closely examine which biologic risk factors are associ-
ated with this progression. Instead, the previous work
helped to delineate the subgroups at high risk for pro-
gression primarily on the basis of duplex scan criteria.
Although large cross-sectional studies have consis-
tently associated age, sex, blood pressure, serum cho-
lesterol, and smoking with the presence of carotid
atherosclerosis, these associations are made on the
basis of one duplex scan examination per patient.6-10
Because serial duplex scanning was not performed,
the effect of these risk factors on disease progression
remains unknown.
In this prospective study of a large cohort of
patients with carotid stenosis, we attempted to
define potentially modifiable cardiovascular risk fac-
tors that are predictive of progression of carotid
stenosis. Although our previous paper primarily rec-
ognized the anatomic risk factors that are associated
with progression, this paper seeks to identify the bio-
logic risk factors that are associated with progression
in an effort to focus preventive intervention and to
alter the natural history of carotid disease.
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Purpose: The purpose of this study was to determine the etiologic factors in the pro-
gression of carotid stenosis.
Methods: We performed prospective serial duplex scan surveillance of 1470 carotid arter-
ies in 905 asymptomatic patients during a 10-year period, with an average follow-up
interval of 29 months and an average of 3.0 scans per carotid artery. Vascular laborato-
ry and hospital records were used to collect risk factor information. The data were ana-
lyzed with proportional hazards modeling.
Results: We examined several demographic, clinical, and laboratory risk factors that were
chosen because of their potential relevance to atherosclerotic disease. These factors were
analyzed with univariate proportional hazards modeling, in which time to progression
of stenosis was the outcome variable. The six significant predictors (P < .05) were age,
sex, systolic pressure, pulse pressure (systolic pressure – diastolic pressure), total choles-
terol, and high-density lipoprotein (HDL). All, except HDL, were positive predictors of
time to disease progression. With multivariate modeling, only pulse pressure and HDL
remained as significant independent predictors of stenosis progression. The risk ratio for
a 10–mm Hg rise in pulse pressure was 1.12, and the risk ratio for a 10-mg/dL decrease
in HDL was 1.20.
Conclusion: In this large cohort of patients who were followed prospectively for carotid
stenosis, pulse pressure and HDL were found to be the key risk factors for carotid steno-
sis progression. The fact that pulse pressure superseded systolic pressure in multivariate
modeling may shed light on the biology of carotid plaque progression. Further, our iden-
tification of these modifiable risk factors may help in the design of therapeutic trials for
the prevention of progression of carotid atherosclerosis. (J Vasc Surg 2000;31:31-8.)
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PATIENTS AND METHODS
The study period encompasses the 10-year inter-
val from September 1988 to September 1997, dur-
ing which time the noninvasive laboratory at the
Pittsburgh Veteran’s Administration Medical Center
performed 6775 carotid duplex scan studies in 4171
patients. Of these patients, 1004 were asymptomatic
at the time of the initial study and had at least one
follow-up study more than 6 months after the base-
line study and at least one carotid artery that had not
undergone carotid endarterectomy (CEA). The
patients were considered to be asymptomatic if they
had absence of transient ischemic attack, amaurosis
fugax, or stroke in the 6-month interval before the
baseline study. The initial patient referral to the lab-
oratory was done by internists and surgeons for var-
ied indications. Although the patients’ physicians
ordered some of the follow-up studies, most studies
were performed because the laboratory schedules
routine follow-up appointments for all patients at
intervals of 6 to 12 months. This is the result of a
prospective strategy to track the clinical and ultra-
sound scan course of these patients.
Carotid arteries that had undergone CEA before
the baseline study were excluded from analysis. In
addition, if a patient underwent CEA after the baseline
study, the stenosis data after the CEA were excluded
from analysis. As we noted in a previous publication,5
we have had a policy for the last 8 to 10 years of offer-
ing CEA to patients at good risk with severe (≥80%)
stenosis. However, several asymptomatic severe lesions
were followed among patients who declined surgery or
among those with significant medical risk factors.
At each patient’s visit to the laboratory, a regis-
tered nurse would obtain a detailed neurologic histo-
ry and yes/no responses to questions about smoking,
hypertension, hyperlipidemia, and diabetes. Blood
pressure in both arms was obtained, and a carotid
duplex scan study (Accuson 128XP, Mountain View,
Calif) was performed. The degree of internal carotid
artery (ICA) stenosis was determined on the basis of
velocity criteria that were validated at our institution
by means of comparison with contrast angiography,5
yielding stenosis categories of none (0 to 14% steno-
sis), mild (15% to 49%), moderate (50% to 79%),
severe (80% to 99%), preocclusive, and occluded.
With angiography as a gold standard, sensitivity and
specificity with our criteria ranged from 70% to 99%.5
In addition, we found excellent overall agreement
between duplex scan and angiography (κ = 0.85).5
Sensitivity, specificity, and kappa statistic were deter-
mined after the review of 487 ICAs that were visual-
ized in 248 consecutive carotid angiograms per-
formed during a 4-year period (October 1993 to
June 1997). The angiographic data were compared
with the respective duplex scan study results.5
To capture only the progression events of poten-
tial clinical significance, we defined progression as an
increase in ICA stenosis to ≥ 50% for carotid arteries
with baseline stenosis < 50% or an increase to a high-
er category of stenosis if the baseline stenosis was ≥
50%. Thus, a transition from the category of no
stenosis to the category of mild stenosis was not
considered as progression but all other increases in
stenosis category were considered as progression.
As previously reported,5 the vascular laboratory
data were extracted into Access (Microsoft, Redmond,
Wash), a relational database. The total cholesterol,
low-density lipoprotein cholesterol (LDL), and high-
density lipoprotein cholesterol (HDL), hemoglobin
A1C (HbA1C), and medication data were retrieved
from the hospital’s central computing system and then
imported into Access. Our intent was that all the
patients would have at least one cholesterol profile
within the first 6 months after their first carotid duplex
scan study. However, some patients refused and others
missed appointments to have cholesterol testing. Of
the 1004 patients, 905 patients (90%) had at least one
cholesterol profile during the period of serial carotid
study. The mean interval between the baseline study
and the first cholesterol profile was 5.8 months. The
analysis of etiologic factors is limited to this subset of
905 patients (1470 carotid arteries). Among these 905
patients, 277 (30.6% of the patients, and 63% of
patients with known diabetes) had HbA1C determi-
nations. All of the other analyzed variables (age, sex,
race, systolic pressure, diastolic pressure, pulse pres-
sure, history of diabetes, history of hyperlipidemia, his-
tory of hypertension, obesity, and smoking status)
were available in all 905 patients. For the patients in
whom more than one cholesterol profile or HbA1C
test were performed during the period of serial carotid
study, the mean value for each laboratory value was
used in the analysis.
We used Access for descriptive statistics, SAS (SAS
Institute, Cary, NC) for Cox proportional hazards
regression modeling and Kaplan-Meier method plots,
and Excel (Microsoft) for exponential curve fitting of
the Kaplan-Meier method plots. Progression was con-
sidered to be an outcome event for the involved
carotid artery, in the same way that death is treated in
a mortality study. A carotid artery was considered to
be withdrawn if CEA was performed after the baseline
study and at the point of the last serial duplex scan
study. Kaplan-Meier method plots were carried out to
the time point when the standard error reached 10%
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of the value of the survival distribution function.
Statistical significance was inferred at the .05 level.
RESULTS
We followed 1701 carotid arteries among 1004
total patients, identified as described previously. The
baseline demographic and clinical characteristics were
typical for patients followed in major vascular labora-
tories, with the exception of the predominant male
gender of the Veterans Administration hospital setting
(Table I). Table I also shows a relative predominance
of low-grade (none or mild) baseline stenosis among
these patients. The mean follow-up period of the
patients was 28 months, and the mean number of
scans per patient was 2.9. The risk of progression
among all ICAs was found to increase steadily from
the time of entry for as long as 7 years of follow-up
examination. These data closely follow an exponential
curve (correlation coefficient, 0.99), with an annual-
ized progression rate of 9.3% of the at-risk population.
Of the 3471 follow-up duplex scan studies, 91
(2.6%) showed regression of the degree of stenosis.
Thirty-two of these instances of regression occurred
among the 328 patients who demonstrated progres-
sion in this study and had at least one post-progres-
sion duplex scan study. Thus, the incidence rate of
“fall-back” of stenosis after progression was 9.8% (32
of 328). These patients were included in our analysis
because it is reasonable to assume that the some
degree of “fall-back” will be found in any real-world
setting. Even if these patients had been excluded, our
results would not have been substantively altered.
Test reproducibility at our vascular laboratory is com-
parable with other excellent centers, with a 92% inci-
dence rate of the same degree of stenosis on repeat
examinations performed less than 30 days apart.5
Therefore, it is likely that most cases of observed
regression represent true plaque regression.
As discussed in the previous section, the analysis
of etiologic factors was limited to 905 patients (1470
carotid arteries) who had at least one complete cho-
lesterol profile (total cholesterol, LDL, HDL) per-
formed during the period in which they were fol-
lowed for carotid stenosis. This group represents 90%
of the entire cohort of 1004 patients. Among this
subset, the mean follow-up period was 30 months
and the mean number of scans per patient was 3.0
(not significantly different from the values for the
entire cohort of 1004 patients). The demographic
features of this group were also not significantly dif-
ferent from those of the entire cohort.
Our initial analytic strategy was to use univariate
proportional hazards modeling to determine the pre-
dictive value of 15 variables that may have an etio-
logic role in the progression of atherosclerosis (Table
II). Of these variables, six had statistically significant
effects on the time to progression. HDL was found
to be a negative predictor of the time to progression
(risk ratio, <1), but the other five variables (age, male
sex, systolic blood pressure, pulse pressure, and total
cholesterol) were positive predictors (risk ratio, >1).
All six variables were entered into a stepwise multi-
variate model, and two (pulse pressure and HDL)
were found to retain independent predictive value for
the time to progression. These variables are indicated
with boldfacing in Table II. The remaining variables
failed to retain significant predictive value in the mul-
tivariate model. The risk ratio for a 10–mm Hg rise
in pulse pressure was 1.12, whereas the risk ratio for
a 10-mg/dL fall in HDL was 1.20.
To further define the importance of HDL and
pulse pressure, we stratified patients into the follow-
ing four groups: (1) HDL of 35 mg/dL or more and
pulse pressure of less than 80 mm Hg, (2) HDL of
less than 35 mg/dL and pulse pressure of less than 80
mm Hg, (3) HDL of 35 mg/dL or more and pulse
pressure of 80 mm Hg or more, and (4) HDL of less
than 35 mg/dL and pulse pressure of 80 mm Hg or
more. The Kaplan-Meier method curves for these
four groups of carotid arteries (Fig 1) show the sepa-
rate and cumulative effects of these two risk factors.
Our analysis included 565 patients in whom
both carotid arteries were followed serially and 340
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Table I. Demographic and clinical features
Baseline patient characteristics (n = 1004 patients)
Mean age (years) 65.5
Sex, male 98%
History of:
Angina 33%
Myocardial infarction 35%
Current smoking 42%
Any smoking 90%
Hyperlipidemia 41%
Diabetes 31%
Hypertension 56%
Baseline distribution of ICA stenosis (n = 1701 ICAs)
None 57%
Mild (15% to 49%) 18%
Moderate (50% to 79%) 14%
Severe (80% to 99%) 8%
Preocclusive 2%
Occluded 0%*
ICA, Internal carotid artery.
*Occluded ICAs were excluded from analysis (see Methods sec-
tion).
patients in whom a single carotid artery was fol-
lowed. To address the possibility that the results
were affected by the combination of these two
groups into a single analysis, we separately analyzed
all the left (n = 743) and all the right (n = 727)
carotid arteries. The results with these two separate
analyses were similar to the results of the analysis of
all 1470 carotid arteries together. In each analysis,
HDL and pulse pressure were still the only two vari-
ables that independently predicted the time to pro-
gression in multivariate analysis (HDL, P = .03 for
left and P = .04 for right; pulse pressure, P < .01 for
both left and right).
We attempted to analyze the role of cholesterol-
lowering medications in our patient cohort. The
medication data were available for 595 of the 905
patients (65.7%). Of these 595 patients, 125
(21.0%) underwent cholesterol-lowering therapy
during at least part of the time they were being fol-
lowed for carotid stenosis. With proportional haz-
ards analysis among these 595 patients, the use of
cholesterol-lowering medication was a significant
positive predictor of the time to progression in uni-
variate analysis (P = .03), but it did not retain signif-
icance in multivariate modeling. Total cholesterol
levels were significantly higher among patients who
underwent cholesterol-lowering therapy (P = .04),
and we therefore concluded that the use of the med-
ication was simply serving as a marker for elevated
cholesterol in the univariate analysis. The design of
this study did not allow us to specifically examine the
effect of cholesterol-lowering therapy on carotid
stenosis progression.
DISCUSSION
Large, population-based studies have attempted
to identify those people in the general population
with the highest risk for the development of signifi-
cant carotid stenosis. With the quantification of risk
factors for atherosclerosis and the performance of
carotid duplex scan examinations on the patients,
these studies have associated age, sex, hypertension,
cholesterol, and smoking with the presence of carotid
atherosclerosis.6-13 A single carotid duplex scan was
performed per person, and most results showed early,
hemodynamically insignificant disease. Because fol-
low-up carotid studies were not done, the role of
these risk factors in the progression from early ather-
osclerosis to more significant stenosis was not defined.
Although our cohort was predominantly male
and in a veterans hospital, it is currently the largest
study to associate cardiovascular risk factors with the
progression of carotid stenosis. Similar to the previ-
ously mentioned cross-sectional studies, our univari-
ate analysis identified age, sex, systolic blood pres-
sure, pulse pressure, total cholesterol, and HDL as
risk factors predictive of carotid stenosis progression.
In contrast, elevated LDL levels, a history of hyper-
tension, and a history of smoking, all of which are
considered to be important risk factors for the pres-
ence of carotid stenosis,14 were not associated with
disease progression.
As previously mentioned by Muluk et al,5 male
sex was significantly associated with carotid stenosis
progression in a univariate analysis but failed to
retain importance in the multivariate model.
Because 98% of our population was male, the signif-
icance of these results is questionable. A population
with a greater proportion of women should be
assessed to determine the relevance of gender as a
predictor of carotid disease progression.
Although various cross-sectional studies have cor-
related systolic blood pressure or a history of hyper-
tension with the presence of carotid atherosclerosis,
our results identified systolic blood pressure and pulse
pressure as the blood pressure components predictive
of progressive carotid disease. A history of hyperten-
sion had no association with worsening carotid steno-
sis. In a prior study, Muluk et al5 postulated that ele-
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Fig 1. Kaplan-Meier method curves show probability of
freedom from progression as function of time. Four curves
are result of stratification of carotid arteries with two
dichotomous variables (high-density lipoprotein, ≥35 or
<35 mg/dL; pulse pressure, ≥80 or <80 mm Hg). Numbers
below figure refer to number of at-risk carotid arteries for
each subgroup at 0, 18, 36, and 54 months. HDL, High-
density lipoprotein; PP, pulse pressure.
vated blood pressure measurements were necessary to
identify uncontrolled disease, which may better corre-
late with stenosis progression.
Although both systolic blood pressure and pulse
pressure were significant predictors of progression in
our univariate analysis, only pulse pressure retained its
predictive value in multivariate analysis. Recent stud-
ies of elderly (>60 years) patients have shown a rela-
tionship between pulse pressure and cardiovascular
disease.15-18 In an elderly population, increased elastic
artery stiffness is the primary effect that will cause the
systolic pressure to rise and the diastolic pressure to
fall. Isolated systolic measurements underestimate
arterial wall stiffness, and pulse pressure represents a
pulsatile component of the arterial pressure that more
accurately represents the degree of atherosclerosis.15
After the examination of 300 duplex scan results in
elderly individuals who were hypertensive and nor-
motensive, Franklin et al15 concluded that pulse pres-
sure was the single best blood pressure component to
predict the presence of carotid stenosis. Because pulse
pressure correlates with the degree of arterial stiffness
and the presence of carotid atherosclerosis, it is per-
haps not surprising to discover that it is also the blood
pressure component most predictive of progression
from early disease to more significant stenosis.
The identification of pulse pressure as a risk fac-
tor predictive of carotid disease progression is poten-
tially useful for preventive medical therapy. Sutton-
Tyrrell et al19 found that 71 participants who under-
went treatment with a diuretic or β blocker for blood
pressure control had slower progression of carotid
stenosis when compared with a placebo group.
Although this study suggests that antihypertensive
drug therapy reduces the risk of carotid stenosis pro-
gression, future investigation is needed to expand on
these findings. More recent studies have determined
that acetyl-cholinesterase inhibitors and β blockers
have variable effects on cerebral blood flow depend-
ing on the degree of carotid stenosis present.20,21
However, these same studies have neglected to inves-
tigate whether the drugs have a protective effect
against the progression of stenosis.
Whereas the lack of an association between a his-
tory of hypertension and carotid disease progression
was unexpected, the finding that a history of smok-
ing was unassociated is less surprising. The number
of pack-years of cigarette smoking previously has
been shown to increase the risk for stroke in a dose-
dependent manner.14 In fact, Whisnant et al22 exam-
ined the results of 752 carotid angiograms and deter-
mined that the duration of smoking was the smoking
variable most strongly related to the presence of
carotid artery stenosis. Therefore, it seems reasonable
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Table II. Cox proportional hazards regression model analysis
Entered into
Univariate model multivariate Multivariate model
P Risk  ratio* 95% CI model P Risk ratio* 95% CI
Demographic variables
Age (years)† .03 1.014† 1.00-1.03 yes >.1
Sex, male .03 9.4 1.32-67.1 yes >.1
Race, nonwhite .19 no
Clinical variables
SBP (mm Hg)† .007 1.006† 1.00-1.01 yes >.1
DBP (mm Hg)† .68 no
Pulse pressure (mm Hg)† .001 1.009† 1.00-1.01 yes .0001 1.02† 1.01-1.03
Total cholesterol (mg/dL)† .03 1.003† 1.00-1.01 yes >.1
LDL (mg/dL)† .45 no
HDL (mg/dL)† .006 0.979† 0.96-0.99 yes .03 0.982† 0.97-0.99
HbA1C (%)† .41 no
History of diabetes .07 no
History of hyperlipidemia .052 no
History of hypertension .12 no
Obesity .50 no
Smoking status, current smoker .09 no
Smoking status, never smoked .25 no
*Risk ratio is shown only for variables with statistically significant effect on probability of progression.
†Variables were analyzed as continuous variables. Therefore, the risk ratios for these variables represent the increased risk associated with
a 1 unit increase in the value of variable. This fact is reflected in the apparently “low” values of the risk ratios for these variables.
Unmarked variables were analyzed as dichotomous (no/yes) variables.
Boldfacing indicates variables that retained independent predictive value in the final multivariate model.
CI, Confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; HbA1C, hemoglobin A1C.
to assume that the duration of smoking or the num-
ber of pack-years would be predictive of carotid dis-
ease progression and that the history of smoking
would not. Although our study did not examine
duration or pack-years, a similar, smaller study of
carotid disease progression by Salonen and Salonen23
found that the number of pack-years was associated
with an increase in mean intima-media carotid thick-
ness over time. Because stroke risk decreases 2 to 5
years after smoking cessation,14 it is possible that the
same beneficial effect could exist for carotid stenosis
progression. Further data accumulation in a popula-
tion with a higher proportion of nonsmokers is need-
ed to test this hypothesis. Ninety percent of our pop-
ulation had admitted to smoking at some point in
time, a fact that makes our cohort less than ideal for
an analysis of smoking as a risk factor.
Total cholesterol, LDL, and HDL have all been
associated with an increased risk of carotid stenosis. In
our multivariate analysis, a decreased HDL level was
the only blood lipid level significant for progression of
carotid stenosis. One reason for this result could be
our elderly study cohort. HDL levels appear to be rel-
atively stable throughout life, and LDL and total cho-
lesterol levels peak from age 45 to 60 years in
American men and decline thereafter.24,25 The stabil-
ity of HDL levels over time allows for a more consis-
tent association with the risk of carotid stenosis pro-
gression in men over the age of 60 years.19,26,27
In an attempt to prevent the progression of carotid
stenosis, several studies have shown that the prolonged
use of cholesterol-lowering medications is associated
with carotid wall thinning.28-31 However, these stud-
ies correlate a decrease in carotid wall thickness with
different blood lipid levels. Mack et al30 associated an
increased HDL level with improved carotid disease,
and Crouse et al31 found a decreased LDL level to be
predictive of carotid wall thinning. This discrepancy
could be caused by the different degree of stenosis pre-
sent in each cohort. Unfortunately, the role that
lipoproteins play in the reversal of early lesions versus
advanced, severe lesions is poorly understood.
Elevated glycosylated hemoglobin (HbA1c) levels
have been associated with carotid atherosclerosis in
both individuals who are diabetic and individuals who
are not diabetic.32,33 However, our results did not
show any association between increased HbA1c levels
and the progression of carotid disease. An assessment
of diabetic control over time with multiple HbA1c
levels may better correlate with the degree of worsen-
ing carotid stenosis. It is unknown whether the strict
control of diabetes will alter the progression of carotid
disease and reduce the primary stroke risk.14
CONCLUSION
In conclusion, elevated pulse pressure and
decreased HDL levels correlate with a higher risk for
worsening carotid stenosis over time. Modification
of these risk factors with medical therapy may pre-
vent the natural progression of carotid stenosis and
reduce the chance of stroke. We suggest that special
attention be paid to these factors in the design of
therapeutic trials for patients with carotid stenosis.
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Dr Joseph H. Rapp (San Francisco, Calif). Dr Muluk
and his associates have analyzed the atherosclerotic risk pro-
files of patients who undergo ultrasound scan studies for
asymptomatic carotid stenosis. Although their list of risk fac-
tors analyzed seems short by today’s standards, the authors
did include the three classic factors: blood pressure, plasma
lipid levels, and smoking history or tobacco use. The authors
found that although several factors were associated with
plaque progression with univariant analysis, only a low level
of high-density lipoprotein (HDL) and a wide pulse pressure
were associated when multivariant analysis was used.
These findings are not all that surprising. HDL and the
major apoprotein component of HDL, apo A-1, have
repeatedly been found, as the author pointed out, to be
powerful predictors of atherosclerosis progression. HDL is
involved in reverse cholesterol transport, which returns cho-
lesterol to the liver for excretion. Low HDLs also can reflect
elevated triglyceride-rich lipoproteins, an independent risk
factor for peripheral vascular disease. Possibly even more
important, HDL can act as a potent antioxidant, is a potent
anti-inflammatory agent, and has been shown to protect
animals from septic shock when present in high amounts.
The basic data that suggest that pulse pressure is an
important player in the atherogenic milieu are equally inter-
esting. Wide pulse pressure drives macromolecules across
cell membranes in tissue culture, and it also may amplify the
mechanical stresses on the arterial wall.
The findings of this paper are intuitively clear and may
help us define a group of patients who are at higher risk
for plaque progression, but there are several issues that I
have asked the authors to clarify.
First, it is clear that the study group contains patients
who had only one carotid artery entered into the study and
patients who had two carotid arteries entered. Given that
you are comparing the effect of systemic factors on plaque
progression, this could be a statistical nightmare. How did
you handle this problem?
Second, during the decade of your study, lipid-lowering
agents became one of the most commonly prescribed classes
of drugs in the Veterans Administration system. Although
this is unlikely to change your findings regarding HDL, it
would lower LDL levels and possibly make that value seem
less prominent in the analysis. How many of your patients
were undergoing treatment with lipid-lowering drugs and
for how long?
Third, as in most Veterans Administration populations,
DISCUSSION
90% of your patients were smokers. Your study claims that
only 42% were actively smoking. I hope patients in
Pittsburgh are more honest than they are in San Francisco,
because my patients are notorious liars when it comes to
reporting active smoking. I wonder how valid it is to claim
that HDL levels and pulse pressure are more important than
smoking tobacco in causing carotid plaque progression?
Finally, you suggest that we might modify low HDL
and wide pulse pressure and thereby slow the progression
of carotid stenosis. I am certain that this is true because
HDL levels and pulse pressure are among the most diffi-
cult risk factors to alter. In fact, if your findings are correct,
it suggests that once these patients have significant ather-
osclerotic plaque develop at the carotid bifurcation, pro-
gression of these lesions is virtually inevitable.
I thank the Society for the privilege of discussing this
interesting paper.
Dr Satish C. Muluk. Dr Rapp, I thank you for your
comments. I will try to answer them in sequence.
The first is an important statistical issue in terms of
combining the patients who contributed two carotid
arteries with those who contributed one carotid artery.
There is the potential for bias under certain circumstances.
We combined them because we were looking at progres-
sion events in an artery and not patient outcomes. And so
our statisticians advised us that combining was the best
way to capture all of the available progression data.
We did analyze the left and right carotid arteries com-
pletely separately from one another, so we had separate
analyses of left and right. And the conclusions were the
same. The same independent risk factors were shown to be
important. Because of that, we believed that it continued
to be valid to combine the two groups in this manner.
The issue of cholesterol-lowering therapy is an impor-
tant one. Unfortunately, it is one that is not possible for us
to definitively answer. I can tell you that we have medication
data on 565 of the 905 patients. And of that group on whom
we have medication data, 21% were undergoing cholesterol-
lowering therapy. The nature of our dataset does not let us
say how long they were undergoing therapy, unfortunately,
until we are able to accumulate more data on this issue. We
can say that cholesterol-lowering therapy was actually a pos-
itive predictor of progression. That may simply be because
cholesterol therapy was a marker for a high cholesterol level,
and we are not suggesting that therapy increases the risk of
progression. It is probably the reverse. But our study is not
designed to answer that question in a definitive way.
The issue of smoking is, of course, very important. And
even though only 42% said they were smoking, I suspect that
quitting may mean that they simply quit in the last 2 days or
something of that sort. I do not doubt that we understate
the percentage of smokers. Because there is such a high pro-
portion of smoking, it may be a background variable that is
not subject to much alterability in any case.
In terms of the alterability of HDL and pulse pressure,
you are absolutely right that HDL is one of the variables that
is very difficult to alter. I would point out though that the
study that used gemfibrozil was successful in raising HDL
and did show a change in stroke outcome in that study. And
there are more tolerable drugs, one of them being Apo A1
Milano, that may be suitable in this regard.
Dr John J. Ricotta (Stony Brook, NY). Dr Muluk,
that was a nice presentation. I missed whether this was a
prospective or a retrospective study?
Dr Muluk. This was a prospective study. The patients
were followed on a prospective strategy to follow them at
every 6-month to 12-month intervals.
Dr Ricotta. And were all the endpoints looked at each
time the patient was seen?
Dr Muluk. The cholesterol data were examined at one or
more intervals. And there was no specific strategy in terms of
the number of cholesterol studies that a patient underwent.
On the other hand, all of the other variables were examined
every study visit, namely, the blood pressure and all of the
other variables.
Dr Ricotta. The final question to follow Dr Rapp’s
comments. Did you look at the status of the contralateral
artery? If the contralateral artery had undergone a carotid
endarterectomy or if there was a high-grade stenosis, did
that affect progression?
Dr Muluk. Absolutely. In fact, we reported previously
that having a contralateral stenosis was an important pre-
dictor of rapid time to progression. We did not include it in
this analysis because we were looking at what we believed
were etiologic or biologic factors that would cause progres-
sion to occur. And we did not perceive the anatomic char-
acter of the opposite side or the ipsilateral side to be in that
category, so we were focused more on etiologic factors in
this study. But the contralateral carotid stenosis is a major
correlate of time to progression.
Dr Jack L. Cronenwett (Lebanon, NH). Dr Muluk,
this is a very powerful dataset. Was it large enough to allow
you to look at the correlation between factors that predict-
ed stenosis and the severity of initial stenosis? In other
words, were there any differences in predictors for patients
who had minimal versus more severe stenosis at outset?
Dr Muluk. In fact, there were. And we reported previ-
ously that having a stenosis of > 50% in the ipsilateral inter-
nal carotid artery or in the ipsilateral external carotid artery
or in the contralateral internal carotid artery were all inde-
pendently correlated with progression. And, in fact, we
believe that those criteria can be used to define subsets of
patients who should be followed more frequently than other
patients. We do not see this data in the same light because
the anatomic features that you see at the end of baseline
study are more powerful predictors of progression than are
these atherosclerotic risk factors. We see these factors instead
as potentially modifiable factors that may have a role in the
biology of why plaques progress.
Dr James M. Estes (Boston, Mass). Did you identify
any correlation between the progression of plaque and the
development of symptoms?
Dr Muluk. In this study, we have not yet done that.
We are looking at symptoms. But the way they are coded
in our dataset, they are incomplete at the moment. So, it
is not possible for us to make any definitive statement
about that. But that is an obvious and very important issue
for us to examine.
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